Many cannabis companies have struggled with declining investor interest amid product delivery shortfalls and adverse revenue reports The distribution obstacles have exacerbated company concerns by creating choking points for inventory, which can quickly lose potency…
Lexaria’s DehydraTECH(TM) drug delivery platform a feasible and healthier alternative to other delivery methods The fast-acting, high absorption technology improves dipping experience and consumer satisfaction Company expects to more than double its 2019 revenue this…
Lexaria’s fast-acting, high absorption technology will improve dipping experience and consumer satisfaction Partnership will enable Lexaria’s to provide its DehydraTECH(TM) drug delivery platform to Cannadips Cannnabis products in California and nationwide Cannadips to open one-of-a-kind…
Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) 2.0 version of its patented DehydraTECH(TM) oral drug-delivery technology has demonstrated its power to deliver more cannabidiol (“CBD”) into the bloodstream than generic industry-control formulations (http://ibn.fm/Utl7A). An article discussing…
Lexaria Bioscience is a company dedicated to developing effective oral ingestion methods for drug substances that rival the rapid-delivery qualities of more health-dangerous inhaled-drug products. Inhalation is a particularly popular method of using tobacco and…
Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, today announced that it has reached a new definitive agreement to provide its patented DehydraTECH(TM) technology to Cannadips’ cannabis products, both in…
Growing interest in the company’s innovative DehydraTECH™ drug delivery platform from large global corporations Lexaria’s strategy to be listed on a nationally recognized U.S. exchange will help the company access a significantly larger audience of…
Lexaria Bioscience continues to advance the effectiveness of its proprietary DehydraTECH technology, a formulation that teams with drug substances such as nicotine and cannabidiol to quickly carry those drugs into a user’s blood stream Recent…
Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, this morning announced that it has reached a definitive agreement to provide its patented DehydraTECH(TM) technology to Cannadips CBD, the Original Smokeless…
Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) innovative DehydraTECH(TM) delivery platform is patented for all nonpsychoactive cannabinoids as well as for tetrahydrocannabinol (THC) and psychoactive cannabinoids. An article discussing the company reads, “Medical researchers have struggled…
Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug-delivery platforms, on Thursday provided a strategic update from the company’s CEO Chris Bunka. Among other highlights, the update includes a brief recap of achievements…
Canada’s first nationally legal cannabis-infused edible products began hitting store shelves December 17, vastly broadening the market for products using the plant’s extracts Lexaria Bioscience has dedicated years of research to the development of its…
DehydraTECH™ drug delivery platform achieved a 319% higher CBD blood concentration level at 60 minutes than the generic coconut oil formulation The technology can be used on the nicotine market, the pharmaceutical market, and the…
Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug-delivery platforms, recently announced further advances in its proprietary, oral, drug-delivery platform: DehydraTECH(TM). An article discussing the company reads, “Lexaria’s early pilot-stage human trials with…
Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) is a global innovator in drug-delivery platforms focused on its patented DehydraTECH-based, drug-delivery technology and formulation development. A recent article discussing the company reads, “Earlier this year, Lexaria moved…
Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator with technology that has demonstrated its ability to enhance the oral delivery of nicotine, recently appointed Gregg Smith, founder of a New York-based culture-tech, venture investment…
Lexaria Bioscience is a company that is passionate about establishing alternatives to inhalation for rapid-response drug substance delivery in order to eliminate the lung harm that smoking or vaping may cause Lexaria’s DehydraTECH platform has…
DehydraTECH™ is patent protected for multiple Active Pharmaceutical Ingredients (APIs) including hemp oil CBD and cannabis, nicotine, non-steroidal anti-inflammatory drugs, and fat-soluble vitamins Lexaria has 16 patents granted and over 60 patent applications pending worldwide…
Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator with technology that has demonstrated its ability to enhance the oral delivery of nicotine, is positioned to benefit from the FDA’s recent announcement that it had…
Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, today announced its development of additional enhancements for its industry-leading DehydraTECH(TM) platform that delivers THC onset of action in less than 10…